Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients

Age Ageing. 2008 Jan;37(1):25-31. doi: 10.1093/ageing/afm141. Epub 2007 Oct 25.

Abstract

Objectives: to evaluate the effects of vitamin D supplementation on parathyroid function and bone turnover in aged, chronically immobile patients.

Design: a randomised double-blind controlled trial.

Subjects: two hundred and eighteen long-term inpatients aged over 65 years.

Intervention: the patients were randomised into treatment groups of I-III, each receiving 0 IU, 400 IU and 1200 IU cholecalciferol per day, respectively. In case of inadequate consumption of dairy products, patients received a daily calcium substitution of 500 mg.

Measurements: plasma concentrations of 25-hydroxyvitamin D (25-OHD), intact parathyroid hormone (PTH), amino-terminal propeptide of type I procollagen (PINP), a marker of bone formation, and carboxy-terminal telopeptide of type I collagen (ICTP), a marker of bone resorption, were measured at baseline and after 6 months.

Results: the patients (age 84.5 years) were chronically bedridden. The baseline 25-OHD was low (23 nmol/l), correlated inversely with PINP, and tended to associate inversely with PTH. The prevalence of vitamin D deficiency (VDD) (25-OHD < 50 nmol/l) was 98% and PTH was elevated in 23% of the patients. Vitamin D supplementation significantly increased 25-OHD concentrations (124% group II, 204% group III) and decreased PTH (-7% group II, -8% group III). PINP tended to decrease, but ICTP tended to increase, and only their ratio decreased significantly. The tendency of ICTP to increase was inconsistent. Changes in 25-OHD correlated inversely with those in PTH and PINP.

Conclusions: vitamin D supplementation has minor effects on PTH and bone turnover in chronically immobilised aged patients with VDD. Further comparative studies and meta-analyses are warranted to elucidate the confounding effects of different mobility levels on the benefits of vitamin D supplementation in patients with differing baseline PTH levels.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bed Rest*
  • Bone Density / drug effects*
  • Calcium / administration & dosage
  • Calcium / blood
  • Cholecalciferol / administration & dosage*
  • Collagen Type I
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Long-Term Care
  • Male
  • Parathyroid Hormone / blood*
  • Peptide Fragments / blood*
  • Peptides
  • Procollagen / blood*
  • Reference Values
  • Treatment Outcome
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood
  • Vitamin D Deficiency / blood*

Substances

  • Collagen Type I
  • Parathyroid Hormone
  • Peptide Fragments
  • Peptides
  • Procollagen
  • collagen type I trimeric cross-linked peptide
  • procollagen Type I N-terminal peptide
  • Vitamin D
  • Cholecalciferol
  • 25-hydroxyvitamin D
  • Calcium